Checkmate Pharmaceuticals
Regeneron is a leading biotechnology company dedicated to using science to develop and deliver innovative medicines for serious diseases. With a focus on genetics, biology, and technology, the company aims to transform science into medicine through proprietary technologies like VelociSuite and collaborations such as the Regeneron Genetics Center. Its mission emphasizes relentless innovation, responsible business practices, and improving human health worldwide.
Industries
Nr. of Employees
Very Large (1000+)
Checkmate Pharmaceuticals
777 Old Saw Mill River Road, Tarrytown, NY 10591, United States
Patents
Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody
US-12344665-B2
View DetailsAnti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
US-12344677-B2
View Details
Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody
US-12344665-B2
View DetailsAnti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
US-12344677-B2
View DetailsProducts
Clinical and commercial biologic medicines
Biologic therapeutic products developed via antibody discovery platforms and manufactured for clinical and commercial use across multiple therapeutic areas.
Investigational genetic medicine candidates
Gene therapy, gene editing and oligonucleotide therapeutic candidates under research and clinical development for central nervous system and other indications.
Bispecific antibody therapeutic candidates
Engineered bispecific antibodies designed to engage two targets with formats developed for manufacturability and clinical evaluation.
Population-scale genomic resources and variant browsers
Publicly accessible summary variant data and web-based variant browsers derived from large sequencing projects to support external research.
Clinical development pipeline (investigational candidates)
A portfolio of investigational candidates in clinical development across multiple therapeutic areas.
Clinical and commercial biologic medicines
Biologic therapeutic products developed via antibody discovery platforms and manufactured for clinical and commercial use across multiple therapeutic areas.
Investigational genetic medicine candidates
Gene therapy, gene editing and oligonucleotide therapeutic candidates under research and clinical development for central nervous system and other indications.
Bispecific antibody therapeutic candidates
Engineered bispecific antibodies designed to engage two targets with formats developed for manufacturability and clinical evaluation.
Population-scale genomic resources and variant browsers
Publicly accessible summary variant data and web-based variant browsers derived from large sequencing projects to support external research.
Clinical development pipeline (investigational candidates)
A portfolio of investigational candidates in clinical development across multiple therapeutic areas.
Services
Framework to provide certain patients access to investigational therapies when no satisfactory alternatives or trials are available.
Programs providing education, insurance eligibility support, financial assistance and donated medicine to eligible patients.
Centralized medical information contact and procedures for reporting adverse events and product complaints.
Partnerships with biobanks, health systems and research consortia to conduct sequencing, proteomics and analytic projects at population scale.
Corporate matching of eligible employee donations to qualified public charities to increase the impact of employee philanthropy.
Organization of volunteer opportunities including global weeks of service and locally coordinated volunteer events supported by regional employee councils.
Framework to provide certain patients access to investigational therapies when no satisfactory alternatives or trials are available.
Programs providing education, insurance eligibility support, financial assistance and donated medicine to eligible patients.
Centralized medical information contact and procedures for reporting adverse events and product complaints.
Partnerships with biobanks, health systems and research consortia to conduct sequencing, proteomics and analytic projects at population scale.
Corporate matching of eligible employee donations to qualified public charities to increase the impact of employee philanthropy.
Organization of volunteer opportunities including global weeks of service and locally coordinated volunteer events supported by regional employee councils.
Expertise Areas
- Population-scale genomics and genetic discovery
- Antibody discovery, engineering and bispecific development
- Biologics manufacturing and supply operations
- Genetic medicines development (gene therapy, gene editing, oligonucleotides)
Key Technologies
- Exome sequencing
- Genotyping and imputation analysis
- Population-scale proteomics
- Engineered mouse models for target validation
News & Updates
In January 2022, the FDA amended the EUA for Regeneron's COVID-19 antibody cocktail to exclude its use where variants not susceptible are present. In November 2024, Regeneron voluntarily requested revocation of the EUA.
Regeneron regularly publishes data from its clinical trials, including promising results for treatments like Libtayo and Linvoseltamab, and ongoing research in infectious diseases, oncology, and other areas.
Regeneron encourages its colleagues to publish research in leading scientific journals, contributing to the advancement of science and medicine.
Recognition for Sustainability and Responsibility
Regeneron has been listed on the Dow Jones Sustainability World Index for six consecutive years and the Civic 50 list for eight years, among other recognitions.
In January 2022, the FDA amended the EUA for Regeneron's COVID-19 antibody cocktail to exclude its use where variants not susceptible are present. In November 2024, Regeneron voluntarily requested revocation of the EUA.
Regeneron regularly publishes data from its clinical trials, including promising results for treatments like Libtayo and Linvoseltamab, and ongoing research in infectious diseases, oncology, and other areas.
Regeneron encourages its colleagues to publish research in leading scientific journals, contributing to the advancement of science and medicine.
Recognition for Sustainability and Responsibility
Regeneron has been listed on the Dow Jones Sustainability World Index for six consecutive years and the Civic 50 list for eight years, among other recognitions.